Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Share News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 39.00
Bid: 38.00
Ask: 40.00
Change: 5.00 (15.15%)
Spread: 2.00 (5.263%)
Open: 33.00
High: 38.00
Low: 34.50
Prev. Close: 33.00
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sareum hails safety profile for SDC-1801 after phase 1 trial

Thu, 15th Feb 2024 11:20

(Alliance News) - Sareum Holdings PLC on Thursday said SDC-1801 has the potential to achieve therapeutically effective dose levels with no serious adverse events, following a phase 1 trial.

Shares in Sareum rose 7.3% to 40.25 pence each in London on Thursday morning.

The Cambridge, England-based pharmaceutical company, which completed the single ascending dose part of a phase 1a clinical trial for SDC-1801, said the study indicated a "favourable profile" and supported the oral dosing of psoriasis patients once a day.

SDC-1801 is a dual TYK2/JAK1 kinase inhibitor, which is being developed as a potential new therapeutic for a range of autoimmune diseases with an initial focus on psoriasis, an autoimmune condition affecting the skin.

Sareum said the study is a randomised, placebo-controlled trial with single and multiple ascending oral dose studies. This trial includes a single ascending dose study, a multiple ascending dose study and a food effects study.

The food effect study part of the trial has also been completed, the firm said, demonstrating no significant food effect on SDC-1801 blood levels.

The multiple ascending dose study is ongoing and full safety data from the Phase 1a clinical trial are expected to be available during the first half of 2024, the company said.

If the results are satisfactory and subject to financing, regulatory requirements, and recruitment preparations, the company will initiate a phase 1b clinical study. It said it would aim to recruit up to 24 psoriasis patients, and have the study completed by the end of 2024.

Chief Executive Officer Tim Mitchell said: "We're pleased to announce that Sareum has cleared an important milestone in this trial. We are encouraged by the preliminary data from the SAD and food effect parts of the phase 1a trial for SDC-1801, which support our confidence in the trial and the broader clinical strategy.

"These are preliminary results but if we continue to see the positive safety profile and pharmacokinetic data we have seen so far, this will underpin our planning for the phase 1b part of the study and beyond. We look forward to the data from the multiple ascending dose part of this trial, which will help us advance towards this critical next point in the study."

By Sabrina Penty, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
19 Apr 2024 12:16

IN BRIEF: Sareum falls as issues shares to RiverFort Global

Sareum Holdings PLC - Cambridge, England-based pharmaceutical company - Issues 3.0 million new shares in the company to RiverFort Global Opportunities PCC Ltd. Issue is in line with facility announced in August. Says facility has an outstanding balance of GBP220,000.

Read more
4 Apr 2024 17:24

TRADING UPDATES: Northcoders launches bootcamp; Schroder invests

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
2 Apr 2024 17:35

TRADING UPDATES: Sareum ups retail offer; SThree nabs former ITV exec

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
28 Mar 2024 13:44

EARNINGS AND TRADING: Northamber loss widens; Ethernity contract boost

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
15 Mar 2024 13:11

Sareum allowed European patent for primary kinase inhibitor asset

(Sharecast News) - Biotechnology company Sareum announced on Friday that the European Patent Office had issued a notice of allowance for a patent concerning SDC‐1801, its primary TYK2/JAK1 kinase inhibitor currently undergoing clinical trials in Australia.

Read more
15 Mar 2024 12:46

Sareum Holdings touts new patent allowance for autoimmune therapy

(Alliance News) - Sareum Holdings PLC on Friday celebrated a new patent allowance for SDC-1801, which is a therapy designed to treat a range of autoimmune diseases.

Read more
12 Mar 2024 15:23

Sareum shares slump on widened loss and funding talks

(Alliance News) - Sareum Holdings PLC share fell on Tuesday, after it said it expects to report a widened interim loss.

Read more
15 Feb 2024 13:22

Sareum reports positive progress in psoriasis programme

(Sharecast News) - Sareum announced significant milestones in its phase 1a clinical trial for SDC-1801, its lead programme aimed at addressing autoimmune diseases such as psoriasis, on Thursday.

Read more
15 Feb 2024 10:52

AIM WINNERS & LOSERS: DSW warns on earnings amid tepid M&A markets

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
2 Jan 2024 13:54

Sareum shares jump on cancer drug licensing deal

(Sharecast News) - Shares in AIM-listed biotech group Sareum jumped by a fifth on Tuesday after its co-development partner for cancer treatment SRA737 signed a commercialisation licence agreement with a US biopharma company.

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 10:05

AIM WINNERS & LOSERS: LungLife AI soars on test; Plexus falls on deal

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
2 Jan 2024 09:31

Sareum soars as partner agrees SRA737 licence with US biopharma firm

(Alliance News) - Sareum Holdings PLC shares surged on Tuesday, after it said its co-development partner CRT Pioneer Fund entered into a development and commercialisation licence for SRA737 with an unnamed US biopharmaceutical company.

Read more
14 Dec 2023 20:20

EARNINGS AND TRADING: CleanTech raises GBP520,000 in open offer

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.